Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cystic fibrosis

M L Aitken1, S B Fiel

  • 1Department of Medicine, University of Washington, Seattle.

Disease-A-Month : DM
|January 1, 1993
PubMed
Summary
This summary is machine-generated.

Cystic fibrosis (CF) is a common genetic disorder affecting multiple organs, primarily the lungs. Advances in treatment have significantly increased patient survival rates, with ongoing research exploring new therapies like gene therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Changes in fecal microbiota with CFTR modulator therapy: A pilot study.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2021
Same author

Men's health in the modern era of cystic fibrosis.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2020
Same author

Rationale and design of a randomized trial of home electronic symptom and lung function monitoring to detect cystic fibrosis pulmonary exacerbations: the early intervention in cystic fibrosis exacerbation (eICE) trial.

Contemporary clinical trials·2013
Same author

Patient-reported respiratory symptoms in cystic fibrosis.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2009
Same author

Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis.

Thorax·2004
Same author

Malignant nerve-sheath tumor with divergent and glandular differentiation in a dog: a case report.

Veterinary pathology·2002
Same journal

Disturbances due to cold.

Disease-a-month : DM·2026
Same journal

GLP-1 agonist and neuroprotection in Stroke and Parkinson's disease: A systematic review.

Disease-a-month : DM·2026
Same journal

GLP-1 receptor agonists for weight management and potential thromboembolic risk reduction in high risk population with cancer, diabetes, cardiovascular disease: A systematic review.

Disease-a-month : DM·2026
Same journal

Periodontal disease and diabetic kidney disease: A comprehensive analysis.

Disease-a-month : DM·2026
Same journal

Foreword for Glucagon-like peptide-1 receptor agonists (GLP-1) and its promise for potential benefits.

Disease-a-month : DM·2026
Same journal

Foreword for insulin autoimmune syndrome (Hirata Disease): An updated review of epidemiology, pathophysiology, clinical features, diagnosis, and management.

Disease-a-month : DM·2026
See all related articles

Area of Science:

  • Genetics
  • Pulmonology
  • Biochemistry

Background:

  • Cystic fibrosis (CF) is an autosomal recessive genetic disorder, most prevalent in Caucasians, affecting approximately 1 in 25 carriers.
  • The CF gene, located on chromosome 7, encodes a membrane protein functioning as an ion channel, with over 230 identified alleles.
  • CF impacts multiple organs, including the lungs, pancreas, and reproductive tract, with pulmonary disease being the primary cause of mortality.

Purpose of the Study:

  • To provide an overview of cystic fibrosis, including its genetic basis, clinical manifestations, and current survival trends.
  • To discuss the complications of pulmonary disease in CF patients and the impact of current treatments.
  • To highlight emerging therapeutic strategies and the potential of future gene therapy.

Main Methods:

Related Experiment Videos

  • Review of existing literature on cystic fibrosis genetics, pathology, and treatment outcomes.
  • Analysis of survival data and trends in cystic fibrosis patient populations.
  • Discussion of ongoing clinical trials for novel CF therapies.

Main Results:

  • Patient survival rates for cystic fibrosis have steadily increased, with mean survival reaching 28 years in 1990.
  • Pulmonary disease, characterized by chronic bacterial colonization and progressive lung damage, remains the leading cause of death.
  • Improved survival is attributed to advancements in antibiotic therapy and nutritional support, including pancreatic enzyme replacements.

Conclusions:

  • Cystic fibrosis management has improved, leading to increased longevity, but pulmonary complications remain critical.
  • Emerging treatments, such as antiproteases, amiloride, and DNase, show promise for managing pulmonary disease.
  • Gene therapy presents a potential future treatment avenue, though safety and technical challenges require further investigation.